Evogene stock fell 2.43 percent as Nasdaq deadline moved

Published on 10/05/2026 at 12:24 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Evogene stock has until March 29, 2027, to restore Nasdaq compliance after a September 30 notice. First-half revenue was USD 0.68 million, down 76.4 percent year over year.

EVGN, IL0011050551, Illustration mit AI erstellt.

Evogene stock (ISIN IL0011050551) was last at USD 0.42 on Nasdaq on October 2, 2026, down 2.43 percent from the prior session. The central issue is the company's new deadline to restore compliance with Nasdaq's minimum bid rule.

Nasdaq grants more time

According to Morningstar on September 30, 2026, Nasdaq granted Evogene an additional 180 calendar days, extending the compliance period to March 29, 2027. The company had previously received until September 28, 2026, to bring its closing bid price back above the USD 1.00 requirement.

Evogene must reach at least USD 1.00 for 10 consecutive business days to regain compliance. The stock's October 2 price of USD 0.42 was 58.0 percent below that threshold, leaving the listing requirement as a material operating consideration rather than a routine administrative detail.

Revenue declines in first half

Seeking Alpha reported on September 28, 2026, that Evogene posted first-half GAAP EPS of negative USD 0.63 and revenue of USD 0.68 million. Revenue fell 76.4 percent from the year-earlier period, placing the listing challenge alongside a sharp contraction in reported sales.

Evogene describes itself as a computational chemistry company using generative artificial intelligence to design small molecules for pharmaceutical and agricultural applications, according to its investor-relations page dated August 18, 2026. Its latest reported quarterly revenue was USD 0.347 million in Q2 2026, while net loss was USD 1.591 million for the quarter.

Stock remains below yearly high

The October 2 trading range was USD 0.41 to USD 0.45, with volume of 146,207 shares. Evogene's 52-week range was USD 0.35 to USD 1.50, so the last price stood 72.0 percent below the yearly high and 20.0 percent above the yearly low.

Evogene's market capitalization was USD 3.7 million as of October 2, 2026. The combination of a USD 1.00 compliance threshold, negative first-half GAAP EPS and a 76.4 percent revenue decline makes the March 29, 2027 deadline the key measurable checkpoint for the stock.